Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis.

Trial Profile

Phase 1B Pilot Safety Study of LiRIS-TM, A Novel Bladder Drug Delivery Platform in Patients With Interstitial Cystitis.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Interstitial cystitis
  • Focus Adverse reactions
  • Sponsors Allergan
  • Most Recent Events

    • 07 Nov 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Apr 2011 NCT reports planned end date as 1 Aug 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top